Transverse tubule remodeling is a hallmark of heart failure. Cardiac bridging integrator 1 (cBIN1) is a circulating membrane scaffolding protein that is essential for transverse tubule health, and its plasma level declines with disease.
H eart failure with preserved ejection fraction (HFpEF) is a growing epidemic worldwide with a high burden of morbidity and mortality. 1 Its incompletely understood pathophysiology has limited development of diagnostic tools to define and follow the disease progression. 2 Cardiac bridging integrator 1 (cBIN1) is a membrane-scaffolding protein in cardiomyocytes that organizes the dyadcontaining microdomains at the transverse tubules that are responsible for the initiation and regulation of systolic and diastolic calcium transients. [3] [4] [5] [6] [7] The level of cBIN1 is reduced in animal models of heart failure, as well as in human biopsy samples from patients with end-stage cardiomyopathy. 3,8-11 Its blood availability makes it an attractive biomarker of cardiomyocyte remodeling. 12 In this study, we demonstrate the performance of the cBIN1 score (CS), a dimensionless index based on the normalized reciprocal of cBIN1 plasma levels, in a population of patients with HFpEF who are stable and ambulatory.
Methods

Study Design
The study was approved by the institutional review board at Cedars-Sinai Medical Center. Full informed consent was obtained from all participants prior to study participation. Participants self-identified their race/ethnicity in the study. Consecutive patients with ambulatory HFpEF were enrolled at the time of continuity visits at the Cedars-Sinai Advanced Heart Failure clinic. The diagnosis of HFpEF was established based on past evidence of objective signs of fluid overload in the absence of noncardiac contributors, as determined by an assessment by an advanced heart failure specialist, prior hospitalization for heart failure, or invasive hemodynamic data confirming presence of elevated cardiac filling pressures. Patients were followed up for at least 1 year by medical record review. Plasma from 2 age-matched and sexmatched control cohorts with detailed clinical histories was obtained from Innovative Research with full informed consent: a healthy cohort with no cardiovascular risk factors and a cohort with presence of HF risk factors but no HFpEF.
The CS was computed as the natural log of the inverse of measured cBIN1 plasma concentration. Plasma sample processing and storage from the heart failure and control cohorts are available in the eMethods in the Supplement.
Statistical Methods
Data distributions were assessed for normality with the quantile-quantile plot and the Kolmogorov-Smirnov test. Normal continuous variables were expressed as means and SDs and compared using a 2-sided t test. Nonnormal continuous variables were analyzed with medians and interquartile ranges (IQRs) and compared using the Mann-Whitney U test. Categorical variables were compared using χ 2 tests. Receiver operating characteristic (ROC) analysis was performed to determine the sensitivity and specificity of CS and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels to identify HFpEF, adjusted for age, sex, and body mass index (BMI; calculated as weight in kilograms divided by height in meters squared). Multiple linear and logistics regression analyses were utilized to determine if model is affected by age, BMI, left ventricular ejection fraction, blood pressure, heart rate, estimated glomerular filtration rate, sex, or race/ethnicity. Since NT-proBNP has a nonnormal distribution, log transformations were used in our analyses. Statistical analyses were conducted using SAS version 9.3.1 (SAS Institute Inc) and RStudio version 1.0.143 (RStudio Inc). Two-sided P values were reported, and a P value <.05 was considered significant.
Results
Study Cohorts
A total of 52 ambulatory patients with HFpEF were age matched and sex matched with 2 control cohorts: healthy individuals with no known cardiovascular risk factors and control participants with at least 1 risk factor (obesity, hypertension, or diabetes) but no heart failure ( 
CS Values and Identification of HFpEF
The distribution of CS values in the healthy control group, riskfactor control group, and the group with HFpEF is in Figure 1A . 
Key Points
Question Can a plasma-based cardiac bridging integrator 1 (cBIN1) score distinguish patients with clinical heart failure with preserved ejection fraction (HFpEF) from healthy individuals and patients with risk factors but no heart failure?
Findings In this study, the cBIN1 score outperformed N-terminal pro-B-type natriuretic peptide in differentiating 52 stable, ambulatory patients with HFpEF from age-matched and sex-matched healthy individuals and participants with heart failure risk factors but no HFpEF.
Meaning If further validated, the cBIN1 score, a marker based not on preload but on maladaptive remodeling of cardiomyocytes, could potentially provide a novel index to identify stable, ambulatory patients with HFpEF. risk-factor control group; P < .001). The levels of NT-proBNP were used for comparison (Table) . Figure 1B ).
To assess the ability of CS and NT-proBNP levels to distinguish patients with HFpEF from those without heart failure, ROC curves were generated with adjustment for age, sex, and BMI. Using the healthy control cohort, CS values yielded an area under the curve (AUC) of 0.98 (95% CI, 0.96-1.00) compared with the AUC for NT-proBNP levels (0.93 [95% CI, 0.88-0.99]; P < .001), and the AUC for the 2 tests combined (0.99 [95% CI, 0.98-1.00]; Figure 2A ). With the risk-factor control cohort as the comparator, CS values similarly outperformed NT- Figure 2B ). Using a CS value of 1.80 as a diagnostic cutoff chosen from the ROC curves (Figure 2A and B) , the CS has positive predictive values of 97% and 100%, and negative predictive values of 68% and 68% against the healthy and risk-factor control cohorts, respectively, for identifying HFpEF diagnosis (Figure 2A and B) .
CS Values and Cardiovascular Hospitalization in Patients With HFpEF
We explored the prognostic ability of the CS for future cardiovascular events in patients with HFpEF. eFigure 1 in the Supplement demonstrates the restricted cubic spline fit for the cardiovascular hospitalizations hazard rate ratio (HRR) compared with CS values. The HRR changes little until the CS value reaches approximately 1.70, at which point it increases and tapers off at a value of approximately 2.29 (P = .04).ACSof1.80, the median CS in the HFpEF cohort, is close to an HRR of unity, and it occurs in the rapid linear rise of the plot. Hence, a CS of 1.80 is used as a cutoff value for outcomes risk stratification. eFigure 2 in the Supplement illustrates cardiovascular hospitalizations for the cohort with HFpEF within 1 year of followup, stratified by CS values greater than or less than 1.80, adjusted for age, sex, BMI, and NT-proBNP level. Patients with CS values equal to or greater than 1.80 have an HRR of 3.8 (95% CI, 1.3-11.2; P = .02) for cardiovascular hospitalization compared with those with CS less than 1.80. The high morbidity and mortality burden of the individuals with HFpEF is illustrated by their 1-year follow-up period, in which there were 27 any-cause hospitalizations, 26 cardiovascular hospitalizations, 5 major adverse cardiovascular events, 3 automatic implantable cardioverter defibrillator discharges, 2 cardiovascular event-associated deaths, 4 heart transplantations, and 1 left ventricular assist device implantation.
Discussion
The prevalence of HFpEF is expected to rise precipitously over the next few decades. 13 Understanding this syndrome has been challenged by the lack of diagnostic tools that can assay cardiac health independent of fluid status. The CS is a cardiac-specific biomarker of transverse tubule remodeling occurring with HF progression. 3, 14, 15 In this study, we show that the CS, a biomarker based on the normalized reciprocal of plasma cBIN1 concentration, is more than 2 SDs higher in stable ambulatory patients with HFpEF compared with age-matched, sex-matched healthy volunteers, as well as individuals with heart failure risk factors but no HFpEF ( Figure 1A) . Notably, CS values are markedly increased even in those patients with New York Heart Association class I and II symptoms, whose NT-proBNP levels are within the age-appropriate normal ranges. Using cubic spline analysis (eFigure 1 in the Supplement) and ROC curve estimate of the test's diagnostic accuracy (eFigure 2 in the Supplement), a cBIN1 cutoff value of 1.80 was chosen for its high positive predictive value for HFpEF diagnosis, as well as its prognostic value for cardiovascular hospitalizations during 1 year of follow-up.
Limitations
Limitations of this study include the heterogeneity of the HFpEF cohort and cBIN1 testing in a single center, without a separate validation cohort. Additionally, the plasma samples from the 2 control cohorts were purchased from a third party. However, our labo- ratory confirmed the stability of the cBIN1 assay under freeze-thaw conditions. Furthermore, we purposefully focused this study of CS values on stable patients in the ambulatory setting, as opposed to patients with acute dyspnea who were presenting to the emergency department, where assessment of NT-proBNP level has proven diagnostic utility.
Conclusions
The potential power of CS is in diagnosing remodeled heart muscle independent of fluid overload. We are encouraged by the synergistic performance of the CS and NT-proBNP level, indicating different mechanistic origins (cardiac muscle health vs volume status, respectively). The receiver operating characteristic curves for the diagnostic performance of the CS and NT-proBNP level demonstrate that combining the 2 assays results in superior discriminating power between patients with heart failure and patients with risk factors but no manifestation of the clinical syndrome. Future directions will further validate CS values for the diagnosis of HFpEF, assess cBIN1 levels in patients with heart failure and reduced ejection fraction, and explore the role of CS in early subclinical HFpEF detection.
I. Supplemental Methods
Definition of Outcomes Studied
Cardiovascular-related hospitalization was defined as any hospitalization due to heart failure, myocardial infarction, revascularization for stable or unstable coronary or peripheral vascular symptoms, stroke or transient ischemic attack (TIA), unstable arrhythmias, ICD firing, cardiovascular death, heart transplantation or implantation of a ventricular assist device (VAD).
Sample Processing for cBIN1 Concentration measurement
All plasma samples for the HF patients were collected at the time of clinic visit(s) and subsequently processed and stored in the Cedars-Sinai Medical Center Heart Institute Biobank per protocol. Whole venous blood was collected into lavender top (EDTA) tubes and stored immediately at 4ºC for less than four hours. Plasma was separated from cellular fraction by spinning tubes in a refrigerated centrifuge at 2,250g for 20 minutes. Then, over ice, 0.5 ml volume of plasma was aliquoted into individual one milliliter de-identified, bar coded cryovials, flash frozen with dry ice and ethanol, and stored in a -80ºC freezer. Clinical data were obtained from chart review and stored in a de-identified Microsoft Access database, indexed by aliquot bar code.
The concentration of cBIN1 was determined using an assay provided by Sarcotein Diagnostics. In brief, a cBIN1 specific sandwich ELISA test was used, which employs a mouse monoclonal anti-BIN1 exon 17 as capture antibody (Sigma-Aldrich) and a HRP-conjugated detection recombinant antibody specific for exon 13 (Sarcotein Diagnostics). 96-well plates were coated with capture antibody, followed by loading with patient plasma samples. To detect the full plasma cBIN1 content from plasma microparticles, each plasma sample was subjected to osmotic shock to break up the microparticles by dilution with distilled water (3 volumes water, 1 volume plasma) before loaded to the ELISA plate 1 . Bound cBIN1 was detected using the HRP-conjugated anti-BIN1 antibody, with concentration determined from known protein standards. The ELISA reagents were purchased from BD Biosciences (BD OptEIA reagents kit, catalog 550534). Using positive control plasma samples with known cBIN1 concentrations, we validated that this assay is highly precise and reproducible with an inter-plate variability of < 5%.
CS Determination
CS is the natural log of the ratio of the predetermined median cBIN1 of a separate large healthy calibration cohort (10ng/ml) to that of measured cBIN1: ln The numerator of 10ng/ml, was the same for all samples run in this study. We express our results as a reciprocal to be consistent with clinical convention of an elevated biomarker to correlate with worsening disease status. Natural log of the ratio is used for CS because the distribution of the ratio, like most biological parameters, is log normal.
NT-proBNP assay NT-proBNP values were obtained from the plasma of two control and one HFpEF cohorts of patients. The Cedars-Sinai Medical Center clinical laboratory sends out the plasma samples to Quest Diagnostics Laboratory to perform the NT-proBNP assay using electrochemiluminescence. NT-proBNP was chosen over BNP due to its superior stability and higher mean recovery (residual immunoreactivity) when obtained from stored frozen plasma. Similarly to CS, a natural log transformation of NT-proBNP was performed and used for analyses.
Statistical Methods
Kaplan-Meier analysis was used to compare the differences in cardiovascular hospitalization rates between patients with high and low levels of CS using the log-rank test. Cox proportional hazards regression models were used to estimate the association between high and low levels of CS and the risk of cardiovascular hospitalization, adjusted for age, sex, BMI, and NT-proBNP. Non-linear relationships between CS and cardiovascular hospitalization were examined with restricted cubic splines using 5 knots located at 0, 0.25, 0.50, 0.75 and 1.00 percentiles. P-value for significance of the fit was derived from the Cox proportional hazard model. 95% confidence intervals were reported.
II.
Supplemental AICD -automated implantable cardioverter defibrillator, BMI -body mass index, HOCM -hypertrophic cardiomyopathy, PADperipheral arterial disease, MI -myocardial infarction, PCI -percutaneous coronary intervention, LVIDd -LV internal diameter in diastole, PASP -pulmonary arterial systolic pressure, K -potassium, eGFR -estimated glomerular filtration rate, LDL -low density lipoprotein, BP -blood pressure, ACEI -angiotensin converting enzyme inhibitor, ARB -angiotensin receptor blocker, STDstandard deviation V. Supplemental Figure 2 eFigure 2. Kaplan-Meier curves for CV hospitalization free survival eFigure 2. Kaplan-Meier curves for cardiovascular (CV) hospitalization free survival. Panel A displays CV hospitalization free survival for the HFpEF patients using a CS cut-off value of 1.8, the median CS value in this cohort (hazard ratio (HR) 3.8, 95% CI 1.3 -11.2, p = 0.015 r ≥ 1.8 ver < 1.8). Pa e ex ibi e Ka a -Meier curves for the HFpEF patients using a combination of the CS and NT-proBNP assays with cut-off values of 1.8 and 300 pg/mL respectively. This panel suggests that prognostication of CV hospitalizations within 1 year of follow-up in the studied cohort can be strengthened by combining the two diag ic e ( ≥ 1.8 a d NT-r NP ≥ 300 g/m a a cia ed i a HR 21.4 c m ared < 1.8 a d NT-proBNP < 300 pg/ml, 95% CI 2.7 -171.6, p = 0.004).
